58A2E073-D3DE-44B2-9065-3DE14B53B3A2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.754270696452036
- age_years
- 34
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.656
- MYC_TARGETS_V2+0.618
- E2F_TARGETS+0.592
- G2M_CHECKPOINT+0.544
- DNA_REPAIR+0.540
- UNFOLDED_PROTEIN_RESPONSE+0.500
- OXIDATIVE_PHOSPHORYLATION+0.492
- NOTCH_SIGNALING+0.439
- MTORC1_SIGNALING+0.413
- WNT_BETA_CATENIN_SIGNALING+0.349
Top 10 suppressed
- KRAS_SIGNALING_DN-0.419
- MYOGENESIS-0.304
- UV_RESPONSE_DN-0.235
- ESTROGEN_RESPONSE_EARLY-0.185
- SPERMATOGENESIS-0.185
- BILE_ACID_METABOLISM-0.167
- APICAL_SURFACE-0.166
- APICAL_JUNCTION-0.160
- INFLAMMATORY_RESPONSE-0.138
- INTERFERON_ALPHA_RESPONSE-0.108
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.930 |
| 2 | 113340B4-B092-4B8C-8A13-5932525B0C33 | — | — | 0.923 |
| 3 | 8F828A42-3E60-40C1-9E7D-428ABEA6C72F | — | — | 0.916 |
| 4 | C8E7072F-6FBB-4BF8-8917-0C0CBDAF7605 | — | — | 0.903 |
| 5 | FB7673F7-FF7F-4C3C-A8C6-9C11C6BB71D5 | — | — | 0.900 |
| 6 | 109ABE6B-033D-47E8-A03A-D285BE82C17B | — | — | 0.900 |
| 7 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.896 |
| 8 | AA605CB6-ABD9-4802-8784-75A18A74C87B | — | — | 0.889 |
| 9 | 1FB9316D-4674-4D97-A33B-649F53D09487 | — | — | 0.882 |
| 10 | 23F34B20-F029-44F5-B3B5-06A74FC0FC9D | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.656 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.618 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.592 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.544 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.540 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.500 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.492 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.439 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.413 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.349 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.315 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.281 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.265 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.243 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.239 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.228 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.207 | Inavolisib | — uncovered |
| APOPTOSIS | 0.192 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.188 | Inavolisib | — uncovered |
| HYPOXIA | 0.166 | Idelalisib | — uncovered |